As KP exhibits the ability to impede the tumorigenic influence of EGFR and IL-6 signaling in HeLa cells, we believe that KP could be a good candidate to be developed as an agent for treating HPV18-positive cervical cancer. This evidence concerns the gene IL6 and cervical carcinoma.